High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles

Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Van, 2007, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer, J Clin Oncol, 25, 1658, 10.1200/JCO.2006.08.1620 Karapetis, 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med, 359, 1757, 10.1056/NEJMoa0804385 Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 26, 1626, 10.1200/JCO.2007.14.7116 Messersmith, 2008, Targeting EGFR in colorectal cancer, N Engl J Med, 359, 1834, 10.1056/NEJMe0806778 Jarry, 2004, Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E, Mol Cell Probes, 18, 349, 10.1016/j.mcp.2004.05.004 Oldenburg, 2008, Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA, J Invest Dermatol, 128, 398, 10.1038/sj.jid.5700920 Dominguez, 2005, Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens, Oncogene, 24, 6830, 10.1038/sj.onc.1208832 Fox Edward A. Preparation of DNA from fixed, paraffin embedded tissue. 1996. Di Giusto, 2004, Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays, Nucleic Acids Res, 32, e32, 10.1093/nar/gnh036 You, 2006, Design of LNA probes that improve mismatch discrimination, Nucleic Acids Res, 34, e60, 10.1093/nar/gkl175 Wong, 2008, Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies, J Clin Oncol, 26, 5668, 10.1200/JCO.2008.19.5024 Hurst, 2009, A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene, BMC Res Notes, 2, 66, 10.1186/1756-0500-2-66 Di, 2007, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy, Br J Cancer, 96, 1166, 10.1038/sj.bjc.6603685 Wiedmann, 1994, Ligase chain reaction (LCR) – overview and applications, PCR Methods Appl, 3, S51, 10.1101/gr.3.4.S51 Osiowy, 2002, Sensitive detection of HBsAg mutants by a gap ligase chain reaction assay, J Clin Microbiol, 40, 2566, 10.1128/JCM.40.7.2566-2571.2002 Lalonde, 2007, Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies, J Clin Microbiol, 45, 2604, 10.1128/JCM.00431-07 Schimanski, 1999, Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver, Cancer Res, 59, 5169 Schuermann, 2003, Detection of K-ras and p53 mutations by “mutant-enriched” PCR-RFLP, Methods Mol Med, 75, 325 Latorra, 2003, Design considerations and effects of LNA in PCR primers, Mol Cell Probes, 17, 253, 10.1016/S0890-8508(03)00062-8 Mouritzen, 2003, Single nucleotide polymorphism genotyping using locked nucleic acid (LNA), Expert Rev Mol Diagn, 3, 27, 10.1586/14737159.3.1.27